Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.

Publication Type:

Journal Article

Source:

Current opinion in HIV and AIDS, Volume 5, Issue 5, p.357-61 (2010)

Keywords:

2010, Adenoviruses, Human, AIDS Vaccines, Americas, Australia, Caribbean Region, Center-Authored Paper, Female, gag Gene Products, Human Immunodeficiency Virus, Genetic Vectors, HIV Infections, Humans, Incidence, Male, nef Gene Products, Human Immunodeficiency Virus, Placebos, pol Gene Products, Human Immunodeficiency Virus, South Africa, Vaccine and Infectious Disease Division, Viral Load

Abstract:

Two phase IIb test-of-concept studies evaluated the replication-defective adenovirus type 5 (Ad5) vaccine MRK gag/pol/nef HIV vaccine to prevent infection or decrease early plasma viral load in disparate populations. The STEP study enrolled men and women in the Americas, Caribbean and Australia; the Phambili trial enrolled men and women in South Africa, where the modes of sexual transmission and HIV-1 risk, subtypes of HIV-1, and background Ad5 seroprevalence differed.